无地塞米松达雷妥尤单抗-伊沙佐米方案治疗虚弱老年复发难治多发性骨髓瘤:IFM 2018-02 II期研究结果
IFM 2018-02是一项在14个IFM中心开展的前瞻性II期试验,评估无地塞米松的达雷妥尤单抗联合伊沙佐米(I-Dara)方案在≥65岁、IMWG虚弱评分≥2、ECOG 0-2的首次或第二次复发的复发难治多发性骨髓瘤患者中的疗效与安全性。55例患者中位年龄82岁,90%超过75岁;≥VGPR率为32%,中位随访35.3个月时中位PFS为19.5个月,中位OS未达到(33.6个月时75%)。≥3级不良事件发生率为67%,安全性可接受。
要点
- I-Dara方案在虚弱老年RRMM中≥VGPR率达32%,中位PFS 19.5个月。
- 中位随访35.3个月时中位OS未达到,33.6个月时OS率为75%。
- ≥3级不良事件发生率67%,以血细胞减少和感染为主,安全性可接受。
核心结论
- I-Dara方案在虚弱老年复发难治多发性骨髓瘤患者中显示出可接受的安全性,缓解率和生存结局在该人群中可接受。
研究设计与样本
- 前瞻性II期试验(IFM 2018-02,NCT03757221),在14个IFM中心开展,纳入55例患者。
- 入组标准:年龄≥65岁,IMWG虚弱评分≥2,ECOG 0-2,首次或第二次复发。
- 治疗方案:达雷妥尤单抗16 mg/kg;伊沙佐米4 mg每周第1、8、15天,28天为一周期;联合甲泼尼龙。
- 主要终点:≥非常好的部分缓解(VGPR)率。
主要发现
- 55例患者中位年龄82岁,90%年龄超过75岁。
- ≥VGPR率为32%。
- 中位随访35.3个月,中位无进展生存期19.5个月。
- 中位总生存期未达到:33.6个月时75%。
- ≥3级不良事件发生于36例(67%)患者:血细胞减少18例,感染8例(其中肺炎6例)。
关键数值与推荐
- ≥VGPR率32%。
- 中位PFS 19.5个月(中位随访35.3个月)。
- 中位OS未达到,33.6个月时OS率75%。
- ≥3级不良事件发生率67%(36/55)。
临床怎么用
- 对于虚弱老年复发难治多发性骨髓瘤患者,可考虑无地塞米松的达雷妥尤单抗联合伊沙佐米方案。
- 治疗期间需监测血细胞减少和感染等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of CD38 immunotherapy and proteasome inhibition has shown synergistic activity. Elderly relapsed or refractory multiple myeloma (RRMM) experience worse outcomes due to variabilities in fitness and higher rates of adverse events (AEs) and treatment discontinuations. The Intergroupe Francophone du Myélome (IFM) 2018-02 trial (NCT03757221) evaluated a dexamethasone-free regimen of daratumumab and ixazomib (I-Dara) in elderly frail RRMM. This prospective, phase 2 trial was conducted at 14 IFM centres. Patients aged ≥65 years with International Myeloma Working Group frailty score ≥2 and an Eastern Cooperative Oncology Group 0-2 in first or second relapse received daratumumab 16 mg/kg; ixazomib 4 mg weekly d1, d8, d15 in a 28-day cycle; and methylprednisolone. The primary end-point was ≥ very good partial response (VGPR) rate. Of 55 patients included, the median age was 82 years, with 90% aged over 75. VGPR or better was 32%. With a median follow-up of 35.3 months, the median progression-free survival time was 19.5 months. The median OS was not reached: 75% at 33.6 months. Grade ≥3 AEs occurred in 36 (67%) patients: cytopenias in 18 and infection in 8 (6 pneumonia). The IFM 2018-02 shows that I-Dara demonstrated an acceptable safety profile for this elderly frail RRMM patients' population. The response rates and survival outcomes were acceptable given the studied population.
引用
- Bobin A, Macro M, Touzeau C, et al. A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study. Br J Haematol. 2026. PMID: 42097596. doi:10.1111/bjh.70512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。